Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Pre-HCT in Myelofibrosis
NCT01790295Phase 2Terminated
- Sponsor
- John Mascarenhas
- Start
- Nov 2013
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ruxolitinib in myelofibrosis (MF), sponsored by John Mascarenhas. Started Nov 2013; status: terminated.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01790295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01790295.